Lipid-Lowering Therapy in PURE Poland Cohort Study
The aim of this study is to present data on the use of lipid-lowering therapy (LLT) in relation to calculated cardiovascular risk (CVR) and an additionally defined target LDL-C concentration. The cohort consisted of 1287 participants in the Polish edition of the Prospective Urban and Rural Epidemiol...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/1/60 |
| _version_ | 1797358574159003648 |
|---|---|
| author | Paweł Lubieniecki Maria Wołyniec Katarzyna Połtyn-Zaradna Katarzyna Zatońska Andrzej Szuba |
| author_facet | Paweł Lubieniecki Maria Wołyniec Katarzyna Połtyn-Zaradna Katarzyna Zatońska Andrzej Szuba |
| author_sort | Paweł Lubieniecki |
| collection | DOAJ |
| description | The aim of this study is to present data on the use of lipid-lowering therapy (LLT) in relation to calculated cardiovascular risk (CVR) and an additionally defined target LDL-C concentration. The cohort consisted of 1287 participants in the Polish edition of the Prospective Urban and Rural Epidemiological Study (PURE). CVR was calculated for each participant using the SCORE2 or SCORE2-OP scale, and for patients with diabetes mellitus (DM), chronic kidney disease (CKD) or atherosclerotic cardiovascular disease (ASCVD) according to the respective criteria. In the cohort analysed, 107 of 212 people (50.5%) in the low cardiovascular risk (CVR) group, 284 of 414 people (68.6%) in the moderate CVR group, 562 of 612 people (91.8%) in the high CVR group and 48 of 49 people (98%) in the very high CVR group did not meet the target LDL-c criterion. Of those in the low CVR group, 86% of participants were not receiving lipid-lowering therapy (LLT); in the moderate CVR group, the proportion was 77.8%; in the high CVR group, 68.1% and in the very high CVR group, 75%. In each cardiovascular risk group, participants who did not meet the target LDL-c concentration criterion and did not take LLT made up the larger group. |
| first_indexed | 2024-03-08T15:03:58Z |
| format | Article |
| id | doaj.art-1316f6c7835c44be8ee9d620975b0c6b |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T15:03:58Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-1316f6c7835c44be8ee9d620975b0c6b2024-01-10T15:00:51ZengMDPI AGJournal of Clinical Medicine2077-03832023-12-011316010.3390/jcm13010060Lipid-Lowering Therapy in PURE Poland Cohort StudyPaweł Lubieniecki0Maria Wołyniec1Katarzyna Połtyn-Zaradna2Katarzyna Zatońska3Andrzej Szuba4Clinical Department of Diabetology and Internal Disease, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, PolandDepartment of Social Medicine, Wroclaw Medical University, 50-345 Wrocław, PolandDepartment of Social Medicine, Wroclaw Medical University, 50-345 Wrocław, PolandDepartment of Social Medicine, Wroclaw Medical University, 50-345 Wrocław, PolandClinical Department of Angiology and Internal Disease, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, PolandThe aim of this study is to present data on the use of lipid-lowering therapy (LLT) in relation to calculated cardiovascular risk (CVR) and an additionally defined target LDL-C concentration. The cohort consisted of 1287 participants in the Polish edition of the Prospective Urban and Rural Epidemiological Study (PURE). CVR was calculated for each participant using the SCORE2 or SCORE2-OP scale, and for patients with diabetes mellitus (DM), chronic kidney disease (CKD) or atherosclerotic cardiovascular disease (ASCVD) according to the respective criteria. In the cohort analysed, 107 of 212 people (50.5%) in the low cardiovascular risk (CVR) group, 284 of 414 people (68.6%) in the moderate CVR group, 562 of 612 people (91.8%) in the high CVR group and 48 of 49 people (98%) in the very high CVR group did not meet the target LDL-c criterion. Of those in the low CVR group, 86% of participants were not receiving lipid-lowering therapy (LLT); in the moderate CVR group, the proportion was 77.8%; in the high CVR group, 68.1% and in the very high CVR group, 75%. In each cardiovascular risk group, participants who did not meet the target LDL-c concentration criterion and did not take LLT made up the larger group.https://www.mdpi.com/2077-0383/13/1/60systematic coronary risk evaluation 2prospective urban and rural epidemiological studycardiovascular risklipid-lowering therapy |
| spellingShingle | Paweł Lubieniecki Maria Wołyniec Katarzyna Połtyn-Zaradna Katarzyna Zatońska Andrzej Szuba Lipid-Lowering Therapy in PURE Poland Cohort Study Journal of Clinical Medicine systematic coronary risk evaluation 2 prospective urban and rural epidemiological study cardiovascular risk lipid-lowering therapy |
| title | Lipid-Lowering Therapy in PURE Poland Cohort Study |
| title_full | Lipid-Lowering Therapy in PURE Poland Cohort Study |
| title_fullStr | Lipid-Lowering Therapy in PURE Poland Cohort Study |
| title_full_unstemmed | Lipid-Lowering Therapy in PURE Poland Cohort Study |
| title_short | Lipid-Lowering Therapy in PURE Poland Cohort Study |
| title_sort | lipid lowering therapy in pure poland cohort study |
| topic | systematic coronary risk evaluation 2 prospective urban and rural epidemiological study cardiovascular risk lipid-lowering therapy |
| url | https://www.mdpi.com/2077-0383/13/1/60 |
| work_keys_str_mv | AT pawełlubieniecki lipidloweringtherapyinpurepolandcohortstudy AT mariawołyniec lipidloweringtherapyinpurepolandcohortstudy AT katarzynapołtynzaradna lipidloweringtherapyinpurepolandcohortstudy AT katarzynazatonska lipidloweringtherapyinpurepolandcohortstudy AT andrzejszuba lipidloweringtherapyinpurepolandcohortstudy |